8th July, 2020, 08:30 – 09:00 CET
H&N patients haven´t seen innovation in the disease area for the past 10 years. Those patients face stigma and lack of clear pathways to get early treatment. Are we all doing enough to accelerate the process? How do we make others SEE them?
17th June 2020, 11.00-12.00 CET
While Europe is working on creating a Cancer Plan, many Member States have national cancer plans and other ambitious initiatives. For example, Germany that is one year into its Decade Against Cancer. German institutions for research and healthcare, the private sector, political institutions and civil society are joining forces for cancer research, cancer prevention and improved therapy of cancer patients. Germany aims to cure or control cancer long-term in 75% of patients by 2030.
What can Europe learn from Germany, and what are the key success factors for a government driven multi-stakeholder action to improve cancer care?
10th June, 2020, 08:30 – 09:00 CET
Lung cancer is responsible for 1 in 5 cancer deaths in Europe. Last year, around half a million Europeans were diagnosed with lung cancer and 400,000 people died of the disease. The survival rates are quite low, but thanks to improvements in diagnosis, surgery, radiotherapy and medicines, they are getting better. The question is, should we screen more aggressively for lung cancer now, or not?.
20th December 2019, 9am CET
In France, it takes 530 days between market authorisation and patients having access to a new medicine. It’s 374 days in Spain, 111 in the UK, and 106 in Germany.
In this webinar we discuss the current access challenges to access to new, innovative oncology treatments in Europe, as well as reforming processes to make reimbursement pathways clearer and more efficient. The objective is to foster timely and appropriate access for those patients with unmet medical needs, and increased clarity and certainty around regulatory access decisions.
Duane Schulthess discusses the Impact of the IPI on Patients, Outcomes and Innovation
21 November 2019 2.15pm ET
Vital Transformation has conducted two studies examining the impact of the proposed international reference pricing in Medicare Part D on the world-class innovative biotechnology sector in California and the United States.
Do CAR-T – Chimeric antigen receptor T-cell – therapies have the potential to revolutionise cancer care? These therapies are disrupting traditional concepts of immuno-oncology, manufacturing, delivery and value across Europe. However, for many, there remain a number of open questions that need to be addressed. This session highlighted the transformative potential of these therapies, and sceptical voices who will focus on the unknown variables and where current challenges lie.
23rd of October 13.00-14.00 Eastern US
This webinar presents original research by Vital Transformation that will be peer review published in Therapeutic Innovation and Regulatory Science, showing the devastating impact on R&D, Investments, and patients that will be caused by reference pricing in the United States.
With the increasing use of new regulatory tools, like the FDA’s breakthrough therapy designation, there are increasing demands for European health technology assessors (HTAs) to make an accurate assessment of the long-term value and performance of CAR-T therapies from smaller datasets and shorter outcomes. This webinar will highlight our recent publication in the BMJ, sponsored by ZIN, which showcases a novel approach to harnessing RWE and develops a longitudinal data set that can be used for effectiveness measures, even in orphan conditions. As well, we will kickoff our new research project in Diffuse large B-cell lymphoma (DLBCL) and describe how we will leverage our methodology to measure the effectiveness of the various options for treatment, both in emerging CAR-T treatments, as well as existing chemotherapy regimes and bone-marrow transplants.
Duane Schulthess, managing Director of Vital Transformation, was invited as an expert by POLITICO to participate in “Health Care 2024,” a survey-driven series of online debates in which POLITICO will explore how the European Union can best tackle health policy. In this installment of Health Care 2024 POLITICO asks: Can the EU gain benefits from sharing health data without weakening privacy — and if so, how?
Hosted by GIPC and Vital Transformation Thursday, July 18, 2019 – 4:00 – 5:00 PM Capitol Hill Visitor’s Center (Room 209-08) First St. NE, Washington, DC 20515 We invite you to join us for a discussion on how the International Pricing Index (IPI) penalizes innovation by targeting companies with the most advanced, newest products. Join GIPC and Vital Transformation to discuss the impacts of IPI on patients, outcomes, and innovation.